Actively Recruiting
Long-term Follow-up Study of BHC001 for TDT
Led by Bioray Laboratories · Updated on 2024-03-18
6
Participants Needed
2
Research Sites
751 weeks
Total Duration
On this page
Sponsors
B
Bioray Laboratories
Lead Sponsor
T
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Collaborating Sponsor
AI-Summary
What this Trial Is About
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
CONDITIONS
Official Title
Long-term Follow-up Study of BHC001 for TDT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
- Treated with BRL-101 for therapy of transfusion-dependent b2-thalassemia.
You will not qualify if you...
- There are no exclusion criteria for this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Nanning, Guangxi, China, 530021
Actively Recruiting
2
Xiangya Hospital of Central South University
Changsha, Hunan, China, 510510
Actively Recruiting
Research Team
X
Xiaochen Wang, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here